Sigyn CardioDialysis™
Reduction of Major Adverse Cardiovascular Events (MACE)
Key Facts
About Sigyn Therapeutics
Sigyn Therapeutics is a public, clinical-stage medical device company developing the Sigyn CardioDialysis™ system, a blood purification technology targeting inflammatory and lipid drivers of cardiovascular disease. Founded in 2019, the company's core strategy is to leverage the established dialysis clinic network for potential commercialization, aiming to address a significant unmet need in MACE reduction. Recent corporate activity indicates the company is actively exploring strategic alternatives, including mergers and asset sales, to advance its technology. Leadership includes Chairman & CEO Jim Joyce, an experienced inventor who previously founded Aethlon Medical and secured FDA Breakthrough Device designations.
View full company profile